Serene Bio is supplying an mRNA synthesis service used in the development and production stages of mRNA vaccines. Seorin Bio is a novel coronavirus infection (Corona 19), and its related sales are on the rise as demand for blood system drugs, cold chains, including mRNA, increases.
On the 6th, an official from Seorin Bio said, “We are supplying mRNA synthesis service,” and “the synthesis service is used during the mRNA vaccine development stage or commissioned production.”
The idea of a drug using mRNA, a type of RNA vaccine, a gene vaccine came out about 30 years ago. However, this is the first time Pfizer, Modena, or vaccine has been successfully commercialized and actually administered to humans.
Existing vaccines that use a part of a virus or protein as an antigen have a very complex culture process, but mRNA vaccines can be produced in a short time by finding out the genetic information of a specific virus. This is why the vaccines of Modena and Pfizer were the first to achieve results in clinical trials.
mRNA (messenger RNA) is a genetic information material that acts in the process of synthesizing proteins in organisms.
The mRNA vaccine is an externally synthesized mRNA that has genetic information to make a so-called spike protein in the expression of the corona 19 virus.
Seorin Bio is engaged in an mRNA synthesis service business, which is used when externally synthesizing mRNA with genetic information.
The company provides’mRNA vaccine service’ to domestic bio companies, hospitals, and schools for commercialization of Pfizer’s and Modena’s mRNA vaccines.
In addition, when consignment production of mRNA vaccines is made in Korea, Serene Bio’s mRNA service can be supplied.
Meanwhile, Seorin Bio, which is counted as an mRNA-related stock along with Green Cross Holdings and Hanmi Science, is on the rise in related sales due to Corona 19. An official at Seorin Bio said, “As the corona research and development is revitalized, the demand for mRNA, blood treatment, cold chain, etc. increases, and sales are increasing until the third quarter of this year.”